Libera Bio announced today that it has closed its Seed Round to advance its MPN Technology® into enabling studies and towards the clinic.

  • Antibodies delivered via the MPN Technology® are proven in vivo to bind with intracellular cancer targets and shrink tumors, in preclinical studies
  • Co-developing two antibodies against different KRAS mutations with a top ten pharma
  • Establishing alliances with companies designing novel monoclonal antibodies to deliver them intracellularly using Libera’s MPN Technology®
  • Closing its EUR 1.3 million Seed Round

More information